Clinical-stage biotechnology · Melbourne

Antibodies designed from the structure up.

Lumen Biologics develops engineered antibodies for inflammatory disease. Two programs are in clinical trials; three more are in preclinical development with partners in Australia and Japan.

Our pipeline Investors

SEC-HPLC · LMB-201 · puritySize variants

Peaks found in the sample run
Peak	RT, min	Area %

Pipeline

Five programs, two in the clinic.

Program codes, not product names: none of these is approved for use anywhere.

ProgramAreaDiscoveryPreclinicalPhase 1Phase 2

LMB-201Bispecific antibodyImmunology

LMB-114Monoclonal antibodyDermatology

LMB-330Fc-engineeredRespiratory

LMB-402With partnerGastroenterology

LMB-510PlatformUndisclosed

Investigational only. These programs are in research or clinical trials. Information here is for investors and partners, not medical advice.

Investors

Announcements, as they're lodged.

Price-sensitive announcements are marked.

4 Nov 2026First participant dosed in LMB-201 Phase 2Price sensitivePDF · 380 KB
22 Oct 2026Quarterly activities and cash flow reportPDF · 1.4 MB
30 Sep 2026Research collaboration extended for LMB-402PartneringPDF · 260 KB

Partnering

Platform access, by program.

We license our antibody engineering platform for defined targets. Business development replies within two working days.

partnering@lumen.example